Global Erythropoietin Drugs Market Insights Forecasts to 2033

• The Global Erythropoietin Drugs Market Size was Valued at USD 10.57 Billion in 2023
• The Market Size is Growing at a CAGR of 11% from 2023 to 2033
• The Worldwide Erythropoietin Drugs Market Size is Expected to Reach USD 30.02 Billion by 2033
• Asia Pacific is expected to Grow the fastest during the forecast period

The Global Erythropoietin Drugs Market Size is Anticipated to Exceed USD 30.02 Billion by 2033, Growing at a CAGR of 11% from 2023 to 2033.

Market Overview

Erythropoietin also known as the hematopoietin is a production of red blood cells in the bone marrow through the triggering of the action of the glycoprotein hormones which are responsible for transporting O₂ from the lungs to the rest of the bodily tissues. Erythropoietin is a drug that was developed to treat the anemic conditions caused by end-stage renal disease (ESRD) disease treatments and dialysis procedures. Also, used to treat the anemia induced cancer, multiple myeloma, and HIV-associated anemia. The normal range of administered erythropoietin is from 4 to 24 mu/ml. Furthermore, the increasing prevalence of anemic conditions induced by end-stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART) is the primary factor that propels the growth of the erythropoietin market. When the body's oxygen levels are low, this hormone helps to release them. However, while erythropoietin is an important treatment for anemia, cancer, and HIV, it can also cause kidney tumors, increased blood viscosity, and bone marrow abnormalities. Chronic disorders frequently cause anemia, and erythropoietin is commonly used to treat this condition. Patients with severe anemia, whether or not on dialysis, may utilize erythropoietin to increase their red blood cell count. Therefore, the rising demand of the global erythropoietin drug market during the forecast period to treat anemia and other diseases.

Report Coverage

This research report categorizes the market for the global erythropoietin drugs market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global erythropoietin drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global erythropoietin drugs market.

Driving Factors

Rising awareness of the erythropoietin benefits to propel the growth of the global erythropoietin drug market during the forecast period. The growth can be attributed to increasing the incidence of chronic diseases like cancer, HIV, end-stage renal diseases, anemia, chronic kidney diseases, and bone marrow abnormalities to the expected boost for the global erythropoietin drug markets in the projected period. Increasing use of biosimilars erythropoietin, easily accessible reimbursements, helpful governmental regulations, and increasing public knowledge of the advantages of erythropoietin therapies all contribute to the market's expansion. In addition, the increasing trend of commercialization for erythropoietin is a popular drug market to fuel the industry demand. Also, the rising utilization of erythropoietin drugs as novel therapeutic agents in research institutes for several research purposes is strengthening the growth of the market. Hence, these factors are significantly increasing the growth of the global erythropoietin drugs market during the forecast period.

Restraining Factors

The rising biosimilar competition prices for both patented and biosimilar products have been falling and are likely to decline significantly during the projection period. Sometimes it shows the adverse effects of the erythropoietin drugs. Therefore, these factors are hampering the growth of the global erythropoietin market during the forecast period.

Market Segmentation

The global erythropoietin drugs market share is classified into product type, application, drug class, and end user.

• The epoetin-alfa segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period.

Based on the product type, the global erythropoietin drugs market is divided into epoetin-alfa, epoetin-beta, and darbepoetin-alfa, others. Among these, the epoetin-alfa segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period. The segmental growth can be attributed to the high utilization rate in reducing anemia in people with cancer and chronic renal failure. Its prolonged presence and familiarity among healthcare professionals may help it acquire a larger market share. In addition, epoetin-alfa has been widely utilized in numerous therapeutic settings for the treatment of anemia caused by chronic renal disease, cancer chemotherapy, and other disorders.

• The kidney disorder segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period.    

Based on the application, the global erythropoietin drugs market is divided into hematology, kidney disorder, cancer, and others. Among these, the kidney disorder segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period. The growth can be attributed to the rising prevalence of end-stage kidney diseases and rising the demand for dialysis. The presence of well-developed reimbursement policies for kidney transplants and related disorders is also predicted to propel the erythropoietin drugs market.

• The biologics segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period.

Based on the drug class, the global erythropoietin drugs market is divided into biologics and biosimilars. Among these, the biologics is expected to hold the largest share of the global erythropoietin drugs market during the forecast period. The growth can be attributed to the patent being protected.  

• The hospitals segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period.

Based on the end user, the global erythropoietin drugs market is divided into hospitals and pharmacy. Among these, the hospitals segment is expected to hold the largest share of the global erythropoietin drugs market during the forecast period. The segmental growth can be attributed to the availability and accessibility of erythropoietin drugs. Erythropoietin medications are normally provided via injection, and healthcare professionals, such as doctors and nurses, are in charge of administering them.

Regional Segment Analysis of the Global Erythropoietin Drugs Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• Latin America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global erythropoietin drugs market over the predicted timeframe.

North America is anticipated to hold the largest share of the global erythropoietin drugs market over the predicted timeframe. The regional market is expected to extensively benefit from local organizations that are actively engaged in the development and use of erythropoietin medicines. The presence of the key players, new product development, expansion, and acquisitions are the main strategies used by the organizations in the market. Government initiatives to promote healthcare and continue investment in healthcare development and awareness. Additionally, the U.S. food and drug administration (FDA) has approved numerous erythropoietin drugs for the treatment of anemia, such as Epogen, Aranesp, and Procrit.

Asia Pacific is expected to grow at the fastest pace in the global erythropoietin drugs market during the forecast period. The presence of major corporations in the area, as well as their strategic activities to develop and commercialize new erythropoietin medication products for anemia therapy, are projected to drive market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global erythropoietin drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of overall competition within the market.

List of Key Companies

• BIOCON
• CELLTRION
• Ranbaxy Laboratories LTD.
• Hoffmann-La Roche
• Teva Pharmaceutical Industries LTD.
• Kyowa Hakko Kirin
• Pfizer Inc.
• Emcure Pharmaceuticals
• Johnson and Johnson
• LG Life Sciences LTD.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Amgen INC.
• Roche Diagnostics
• Hospira INC.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In March 2022, Zydus gets DCGI nod for oral drug to treat anemia in CKD patients, OxemiaTM (Desidustat) is a first-of-its-kind oral treatment in India for anemia associated with chronic kidney diseases

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global erythropoietin drugs market based on the below-mentioned segments:  

Global Erythropoietin Drugs Market, By Product Type

• Epoetin-Alfa
• Epoetin-Beta
• Darbepoetin-Alfa
• Others

Global Erythropoietin Drugs Market, By Application

• Hematology
• Kidney Disorder
• Cancer
• Others

Global Erythropoietin Drugs Market, By Drug Class

• Biologics
• Biosimilars

Global Erythropoietin Drugs Market, By End User

• Hospitals
• Pharmacy

Global Erythropoietin Drugs Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa